Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:LEGN NASDAQ:LNTH NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$53.77+0.1%$47.98$21.34▼$58.40$4.30B-0.294.06 million shs640,247 shsLEGNLegend Biotech$31.86+0.6%$33.69$27.34▼$47.79$5.85B0.231.43 million shs1.48 million shsLNTHLantheus$56.06-0.8%$54.14$47.25▼$118.21$3.84B0.091.49 million shs651,643 shsRVMDRevolution Medicines$54.48+1.9%$44.20$29.17▼$62.40$10.18B1.272.15 million shs1.97 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+0.09%-0.13%+13.30%+6.35%+87.55%LEGNLegend Biotech+0.60%-0.31%-3.10%-26.52%-27.51%LNTHLantheus-0.80%+0.83%+5.32%-23.13%-49.33%RVMDRevolution Medicines+1.95%+0.70%+25.13%+43.75%+12.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$53.77+0.1%$47.98$21.34▼$58.40$4.30B-0.294.06 million shs640,247 shsLEGNLegend Biotech$31.86+0.6%$33.69$27.34▼$47.79$5.85B0.231.43 million shs1.48 million shsLNTHLantheus$56.06-0.8%$54.14$47.25▼$118.21$3.84B0.091.49 million shs651,643 shsRVMDRevolution Medicines$54.48+1.9%$44.20$29.17▼$62.40$10.18B1.272.15 million shs1.97 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+0.09%-0.13%+13.30%+6.35%+87.55%LEGNLegend Biotech+0.60%-0.31%-3.10%-26.52%-27.51%LNTHLantheus-0.80%+0.83%+5.32%-23.13%-49.33%RVMDRevolution Medicines+1.95%+0.70%+25.13%+43.75%+12.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 2.31Hold$73.3836.46% UpsideLEGNLegend Biotech 2.73Moderate Buy$66.56108.90% UpsideLNTHLantheus 2.38Hold$74.5032.89% UpsideRVMDRevolution Medicines 3.00Buy$77.5042.25% UpsideCurrent Analyst Ratings BreakdownLatest AKRO, RVMD, LNTH, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025LEGNLegend BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025LNTHLantheusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)10/25/2025RVMDRevolution MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025AKROAkero TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/21/2025RVMDRevolution MedicinesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$90.0010/20/2025RVMDRevolution MedicinesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/17/2025RVMDRevolution MedicinesNational BanksharesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$80.0010/17/2025RVMDRevolution MedicinesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$72.00 ➝ $76.0010/17/2025LEGNLegend BiotechJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$60.0010/17/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $60.0010/17/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$77.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/ALEGNLegend Biotech$627.24M9.38N/AN/A$5.70 per share5.59LNTHLantheus$1.52B2.51$7.03 per share7.97$15.65 per share3.58RVMDRevolution MedicinesN/AN/AN/AN/A$13.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)LNTHLantheus$312.44M$3.7614.918.88N/A17.82%34.06%19.10%11/6/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)Latest AKRO, RVMD, LNTH, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025AKROAkero Therapeutics-$0.94N/AN/AN/AN/AN/A11/11/2025Q3 2025LEGNLegend Biotech-$0.08N/AN/AN/A$277.91 millionN/A11/6/2025Q3 2025LNTHLantheus$1.28N/AN/AN/A$363.42 millionN/A11/5/2025Q3 2025RVMDRevolution Medicines-$1.39N/AN/AN/A$1.81 millionN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0212.6612.66LEGNLegend Biotech0.304.714.57LNTHLantheus0.494.294.07RVMDRevolution Medicines0.1311.7911.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ALEGNLegend Biotech70.89%LNTHLantheus99.06%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%LEGNLegend Biotech0.02%LNTHLantheus1.50%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableLNTHLantheus70067.99 million66.97 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableAKRO, RVMD, LNTH, and LEGN HeadlinesRecent News About These CompaniesRevolution Medicines, Inc. $RVMD Shares Bought by Allianz Asset Management GmbHOctober 24 at 4:12 AM | marketbeat.comMizuho Upgrades Revolution Medicines (NASDAQ:RVMD) to Strong-BuyOctober 23 at 7:13 AM | marketbeat.comVanguard Personalized Indexing Management LLC Has $467,000 Stock Position in Revolution Medicines, Inc. $RVMDOctober 23 at 3:45 AM | marketbeat.comRevolution Medicines: Elironrasib shows’ compelling’ antitumor activity in trialOctober 22 at 3:43 PM | msn.comRevolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C ...October 22 at 3:43 PM | markets.businessinsider.comRevolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C InhibitorOctober 22 at 12:12 PM | globenewswire.comRevolution Medicines pancreatic cancer treatment granted orphan statusOctober 21, 2025 | msn.comMizuho Begins Coverage on Revolution Medicines (NASDAQ:RVMD)October 21, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Up - Should You Buy?October 18, 2025 | marketbeat.comRevolution Medicines' (RVMD) Outperform Rating Reiterated at WedbushOctober 18, 2025 | marketbeat.comWedbush Reiterates Revolution Medicines (RVMD) Outperform RecommendationOctober 18, 2025 | msn.comTD Asset Management Inc Buys 181,724 Shares of Revolution Medicines, Inc. $RVMDOctober 18, 2025 | marketbeat.comRevolution Medicines stock surges after FDA grants priority voucherOctober 17, 2025 | za.investing.comRevolution Medicines price target raised to $80 from $78 at BofAOctober 17, 2025 | msn.comAchieve, Disc, Revolution among winners of initial FDA national priority vouchersOctober 17, 2025 | msn.comWCM Investment Management LLC Grows Stock Position in Revolution Medicines, Inc. $RVMDOctober 17, 2025 | marketbeat.com6,116 Shares in Revolution Medicines, Inc. $RVMD Bought by Bayforest Capital LtdOctober 17, 2025 | marketbeat.comRevolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot ProgramOctober 16, 2025 | globenewswire.comRevolution Medicines (NASDAQ:RVMD) Insider Sells $1,213,500.00 in StockOctober 16, 2025 | marketbeat.comInsider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 25,000 Shares of StockOctober 16, 2025 | insidertrades.com8,423 Shares in Revolution Medicines, Inc. $RVMD Bought by Maryland State Retirement & Pension SystemOctober 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKRO, RVMD, LNTH, and LEGN Company DescriptionsAkero Therapeutics NASDAQ:AKRO$53.77 +0.05 (+0.09%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$53.76 -0.02 (-0.03%) As of 10/24/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Legend Biotech NASDAQ:LEGN$31.86 +0.19 (+0.60%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$32.30 +0.44 (+1.37%) As of 10/24/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Lantheus NASDAQ:LNTH$56.06 -0.45 (-0.80%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$55.83 -0.23 (-0.41%) As of 10/24/2025 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Revolution Medicines NASDAQ:RVMD$54.48 +1.04 (+1.95%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$54.62 +0.14 (+0.25%) As of 10/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
